Top image

CD5-2: Centenary Institute's New Drug to Treat Cancers

Article Type
News Articles
DATE
21 July 2017

After more than 30 years of research Professors Jenny Gamble and Mathew Vadas have developed a new drug that could be effective in some of the hardest to treat cancers with the highest mortality rates, such as pancreatic and liver cancer. Their ground-breaking study has recently been published in the prestigious journal, Cancer Research.

A collaboration between Centenary Institute's Vascular Biology Program and with Mirrx Therapeutics in Denmark, lead to the development of the drug (called CD5-2) and together with other scientists at domestic research institutes in Australia, they have shown that it has potential to be effective and to work alongside the current immunotherapy for cancers. The first-in-class drug, by altering the endothelial cells of the blood vessels within the tumour, allows T cells to penetrate into the tumour and also impacts on the behaviour of these T cells allowing them to more effectively provide their protective function of fighting and killing the cancer cells.

Essential toxicology and safety studies are underway, but it is hoped that this new drug could be in clinical trials, performed in Sydney, in the next 2-3 years.

Credit:  Excerpt taken from"30 years of research on a single cell sees husband and wife team develop new drug to treat cancers with the highest mortality rates", Centenary Institute Media Release 21 July 2017.

Coverage of the research as seen on Nine News

 

Back to list